StonvexLoading…
StonvexStonvexStonvexCore line items from DNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $19.47M | $170.16M | $136.76M | $97.92M |
Operating Income | $-71.37M | $-315.28M | $-244.53M | $-154.51M |
Net Income | $-82.59M | $-312.76M | $-232.01M | $-151.26M |
EPS (Diluted) | $-1.39 | $-5.64 | $-4.22 | $-2.77 |
Total Assets | $1.03B | $1.12B | $1.19B | $1.23B |
Total Liabilities | $589.92M | $611.11M | $629.38M | $618.06M |
Cash & Equivalents | $143.86M | $167.20M | $111.06M | $203.57M |
Free Cash Flow OCF − CapEx | $-48.62M | $-178.72M | $-131.04M | $-99.44M |
Shares Outstanding | 61.66M | 58.21M | 56.84M | 55.43M |